Psilocybin for OCD: The Yale Trial and Early Evidence
About This Video
Overview of psilocybin research for OCD — beginning with the 2006 Moreno pilot (all 9 participants showed significant symptom reduction at all dose levels, including low doses without full psychedelic effects) and continuing through the ongoing Yale randomized controlled trial.
The mechanistic case is explained clearly: OCD involves hyperactivity in circuits mediating error detection and checking behavior, maintained by default mode network-based rumination and rigid self-referential thought. Psilocybin's suppression of the DMN directly addresses the rumination mechanism. The 5-HT2C agonism may also address OCD-specific serotonin dysfunction differently from SSRI-based reuptake inhibition.
The SSRI interaction problem specific to OCD is covered: OCD requires higher SSRI doses than depression, making washout more complicated and risky. The video explains different clinical approaches to this challenge.
Key Takeaways
- The 2006 Moreno pilot (n=9) showed symptom reduction in all participants at all dose levels — the first modern clinical evidence.
- OCD involves rigid, hyperactive self-referential patterns that psilocybin's DMN suppression directly addresses.
- The Yale RCT is the first controlled trial — early results suggest significant Y-BOCS reduction in psilocybin condition.
- OCD's requirement for high-dose SSRIs creates a specific SSRI interaction challenge that clinical trials are working to resolve.
- Integration should include continuation of ERP therapy during the post-session neuroplasticity window.
Dive Deeper
Continue exploring this topic on LearnShrooms: